Strong Results Observed for Adalimumab Biosimilar GP2017 for Inflammatory Bowel Disease

This study provides further support for the efficacy of this biosimilar, allowing for potential future reduction in costs for patients with IBD.

Related Keywords

Italy ,Obanzi ,Basilicata ,Cristina Bezzio , ,Gastroenterology Unit ,Rho Hospital ,Northern Italy ,Turin Hospital ,Adalimumab Biosimilar ,Inflammatory Bowel ,Among Biosimilars ,Ibd ,Biosimilar ,Inflammatory Bowel Disease ,